Cargando…

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer

Estrogen receptor–positive early breast cancer is common and has a relatively good prognosis. It shares risk factors with cardiovascular disease, and cardiovascular disease is an important competing cause of mortality. Adjuvant endocrine therapy with aromatase inhibitors (requiring concomitant ovari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Yee-Ming, Ramchand, Sabashini K, Yeo, Belinda, Grossmann, Mathis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Mini-Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595530/ https://www.ncbi.nlm.nih.gov/pubmed/31259291 http://dx.doi.org/10.1210/js.2019-00096

Ejemplares similares

Genome-Wide Estrogen Receptor Activity in Breast Cancer
por: Farcas, Anca M, et al.
Publicado: (2020)

Advances and Unmet Needs in the Therapeutics of Bone Fragility
por: Ramchand, Sabashini K., et al.
Publicado: (2018)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
por: Howard, Erin W., et al.
Publicado: (2018)

Corrigendum: Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
por: Leung, Euphemia Y., et al.
Publicado: (2017)

Advances in the Development of Prodrugs as Selective Modulators of Estrogen Receptors
por: Pollock, Julie A, et al.
Publicado: (2022)

ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers
por: Nath, Aritro, et al.
Publicado: (2022)

Endocrine Labomas
por: Dutta, Deep, et al.
Publicado: (2012)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

Review of bone health in women with estrogen receptor–positive breast cancer receiving endocrine therapy
por: Malagrinò, Matteo, et al.
Publicado: (2023)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Estrogen receptor subcellular localization and cardiometabolism
por: Gourdy, Pierre, et al.
Publicado: (2018)

Estrogen Receptors in Nonfunctioning Pituitary Neuroendocrine Tumors: Review on Expression and Gonadotroph Functions
por: Haydar Ali Tajuddin, Amalina, et al.
Publicado: (2020)

Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
por: Jeffreys, Sarah A., et al.
Publicado: (2020)

Role of estrogen receptor coregulators in endocrine resistant breast cancer
por: Altwegg, Kristin A., et al.
Publicado: (2021)

Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study
por: Cheung, Yee-Ming M, et al.
Publicado: (2023)

The Importance of Natriuretic Peptides in Cardiometabolic Diseases
por: Vinnakota, Shravya, et al.
Publicado: (2020)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
por: Ellis, Matthew J., et al.
Publicado: (2008)

Endocrine sensitivity of estrogen receptor‐positive breast cancer is negatively correlated with aspartate‐β‐hydroxylase expression
por: Shimoda, Masafumi, et al.
Publicado: (2017)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer
por: Rees, Michael, et al.
Publicado: (2020)

Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy
por: Kawiak, Anna, et al.
Publicado: (2022)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Multiple endocrine neoplasia type 1
por: Thakker, R. V.
Publicado: (2012)

In Silico Predictions of Endocrine Disruptors Properties
por: Schneider, Melanie, et al.
Publicado: (2019)

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer
por: Chan, Melissa, et al.
Publicado: (2015)

Endocrine manipulations in cancer prostate: A review
por: Rajput, Rajesh, et al.
Publicado: (2012)

Endocrine‐disrupting chemicals and male reproductive health
por: Sharma, Aditi, et al.
Publicado: (2020)

Influence of COVID-19 vaccines on endocrine system
por: Zhao, Ying, et al.
Publicado: (2022)

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
por: Sanchez, Cesar G, et al.
Publicado: (2011)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
por: Xie, Yuxin, et al.
Publicado: (2022)

Development of novel agents for the treatment of early estrogen receptor positive breast cancer()
por: Elliott, Mitchell J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rjq5jug9l1tjdp2du7vov458ua